EMBL: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD